Drug details

Menveo (meningococcal (groups a, c, y and w-135) oligosaccharide diphtheria crm197)

type of Vaccines, Inactivated, Bacterial, Vaccines, Travel

Menveo [Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine] is an immunization used to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135.

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• fast heartbeats,
• dizziness,
• weakness,
• high fever,
• unusual behavior, and
• seizures (after receiving the vaccine)

The following drugs are related to Menveo, either as a replacement or used together:

• Vaxelis (diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, haemophilus b conjugate [meningococcal protein conjugate] and hepatitis b [recombinant] vaccine)
• Menactra (polysaccharide diphtheria toxoid conjugate vaccine)
• MenHibrix (meningococcal groups c and y and haemophilus b tetanus toxoid conjugate vaccine)
• MenQuadfi (meningococcal (groups a, c, y, w) vaccine for injection)
• Trumenba (meningococcal group b vaccine)
• Menomune (meningococcal polysaccharide vaccine)